Effect of a Low-Level Laser on Liposomal Doxorubicin Efficacy in a Melanoma Cell Line

Introduction: The cytotoxicity of chemotherapy drugs is a significant challenge in the way of surmounting cancer. Liposomal drug delivery has proven to be efficacious in increasing the function of the drugs. Its potential to accumulate drugs in the target site and enhance the efficiency of anti-cancer agents with lower doses hinders their cytotoxicity on normal healthy cells. Since the release of drugs from liposomes is not generally on a controlled basis, several studies have suggested that external stimuli including lasers could be used to induce controlled release and boost the efficiency of liposomal drug delivery systems (LDDSs). Methods: The A375 cancer cell line was used and exposed to the liposomes containing doxorubicin in the presence of a low-level laser beam to investigate its effect on the liposomal stimuli-responsiveness release and its toxicity on cancer cells. So as to achieve that goal, Annexin V/PI was employed to analyze the number of cells that underwent apoptosis and necrosis. Results: Here, we report the effect of laser irradiation on LDDSs. According to the results obtained from the annexin V/PI assay, the pattern of viability status has shifted, so that the number of pre-apoptotic cells treated with liposomal doxorubicin and a laser beam was more than that of cells treated with only liposomal doxorubicin. Conclusion: The use of stimuli-responsive LDDSs, in this case, laser-responsive, has led to favorable circumstances in the treatment of cancer, offering enhanced cancer cell cytotoxicity.

Download Full-text

Light‐Triggered Cancer Cell Specific Targeting and Liposomal Drug Delivery in a Zebrafish Xenograft Model

Advanced Healthcare Materials ◽

10.1002/adhm.201901489 ◽

2020 ◽

Vol 9 (6) ◽

pp. 1901489 ◽

Cited By ~ 3

Author(s):

Li Kong ◽

Quanchi Chen ◽

Frederick Campbell ◽

Ewa Snaar‐Jagalska ◽

Alexander Kros

Keyword(s):

Drug Delivery ◽

Cancer Cell ◽

Xenograft Model ◽

Liposomal Drug ◽

Specific Targeting ◽

Liposomal Drug Delivery

Download Full-text

PET/CT Imaging of 64CU-Labelled HER2 Liposomal Doxorubicin (64CU-MM-302) Quantifies Variability of Liposomal Drug Delivery to Diverse Tumor Lesions in HER2-Positive Breast Cancer Patients

Annals of Oncology ◽

10.1093/annonc/mdu068.1 ◽

2014 ◽

Vol 25 ◽

pp. i19 ◽

Cited By ~ 5

Author(s):

B. Hendriks ◽

A. Shields ◽

B.A. Siegel ◽

K. Miller ◽

P. Munster ◽

...

Keyword(s):

Breast Cancer ◽

Drug Delivery ◽

Cancer Patients ◽

Liposomal Doxorubicin ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Liposomal Drug ◽

Pet Ct ◽

Liposomal Drug Delivery ◽

Positive Breast Cancer

Download Full-text

Evaluation of Biological Activity of Different Wavelengths of Low-Level Laser Therapy on the Cancer Prostate Cell Line Compared With Cisplatin

Journal of lasers in medical sciences ◽

10.34172/jlms.2021.17 ◽

2021 ◽

Vol 12 (1) ◽

pp. e17-e17

Author(s):

Jaber Zafari ◽

Hossein Abbasinia ◽

Hediyeh Gharehyazi ◽

Fatemeh Javani Jouni ◽

Saeed Jamali ◽

...

Keyword(s):

Prostate Cancer ◽

Cell Viability ◽

Cell Line ◽

Laser Therapy ◽

Cell Lines ◽

Cancer Cell ◽

Lncap Cell ◽

Low Level Laser Therapy ◽

Low Level Laser ◽

Level Laser

Introduction: Cancer is one of the most important problems in the world. Low-level laser therapy (LLLT) has been emerged as a new approach, having both stimulation and inhibition effects on cellular function. The goal of this study was to analyze and compare the different concentrations of cisplatin and wavelengths of laser therapy on the LnCap cell lines. Methods: LnCap cells were cultured and treated with different concentrations of cisplatin (0.1, 0.4, 0.8, 1.2 and 2 µg/mL for 24 hours) and wavelengths of laser therapy (610, 630 and 810 nm) (0.45 J/cm2 ) separately. The viability of cells was examined by MTT assay and IC50 was also calculated. Furthermore, a combination of cisplatin IC50 (24 hours) and different wavelengths of the laser was examined. Results: The results of this study showed that 2 µg/mL of cisplatin has the most significant reduction effect on the cell viability of the LnCap cell line. Cisplatin decreased the viability of cells in a dose-dependent manner. Moreover, IC50 of cisplatin was 1.24 µg/mL. On the other hand, LLLT with wavelengths of 610, 630 and 810 nm did not show notable biological effects on cell viability. Conclusion: As known, cisplatin has the capability to reduce the viability of LnCap cell lines. However, LLLT cannot be a remarkable option for the treatment of prostate cancer. Therefore, although laser therapy showed praiseful therapeutic activity against some cancer cell lines, in this study the results indicated that defined laser wavelengths had no inhibitory effects against the prostate cancer cell line.

Download Full-text